Publications in collaboration with researchers from Universitat Autònoma de Barcelona (12)

2019

  1. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain

    PLoS ONE, Vol. 14, Núm. 11

  2. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

    Antiviral Research, Vol. 170

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2015

  1. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio

    HIV Medicine, Vol. 16, Núm. 6, pp. 370-374

2014

  1. Genetic barrier to resistance for dolutegravir

    AIDS Reviews, Vol. 17, Núm. 1, pp. 59-68

  2. Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing

    Clinical Infectious Diseases, Vol. 59, Núm. 4, pp. 578-588

  3. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2013

  1. Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: The RECOMB study

    HIV Medicine, Vol. 14, Núm. 6, pp. 327-336

2010

  1. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μl in Europe and North America: A pooled cohort observational study

    The Lancet, Vol. 376, Núm. 9738, pp. 340-345

  2. The future of antiretroviral therapy: Challenges and needs

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 5, pp. 827-835

2007

  1. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: The CORAL-1 multicentre pilot study

    Journal of Viral Hepatitis, Vol. 14, Núm. 10, pp. 704-713